All News

Stigma may cause undiagnosed individuals with HIV to go unidentified and fail to get quality care and treatment.

Findings showed that LAIV was more effective in those vaccinated in both the enrollment season and the prior season than in those vaccinated only in the enrollment season.

With the growth of specialty medications and the high-touch care that is needed to ensure optimal outcomes, a niche market focused on providing ancillary services for these drugs has grown in popularity.

Officials with the FDA have approved a new opioid, (Dsuvia, AcelRx Pharmaceuticals), sparking some controversy in the media that the opioid has potential for abuse.

Study identifies potential risk factors for chemotherapy-induced febrile neutropenia in patients with cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Several large investigations have demonstrated the considerable efficacy of TDF/FTC taken daily or intermittently, reducing the risk of HIV acquisition by more than 95% in high-risk individuals.

Lorlatinib approved for patients with ALK-positive metastatic NSCLC who have progressed on crizotinib (Xalkori) and at least 1 other ALK inhibitor for metastatic disease.

This cannabidiol oral solution can be prescribed in the United States to treat seizures associated with Dravet or Lennox-Gastaut syndrome.

The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors.

Although HPV vaccination rates have steadily increased in recent years, more work is needed in this area to effectively reduce HPV-associated cancer, according to a new report release by the President’s Cancer Panel.

Officials with the FDA have approved Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv) for patients with cancer receiving myelosuppressive chemotherapy. The drug is a biosimilar to Amgen’s Neulasta (pegfilgrastim).

Officials with the FDA have approved Coherus BioSciences’ Udenyca™ (pegfilgrastim-cbqv) for patients with cancer receiving myelosuppressive chemotherapy. The drug is a biosimilar to Amgen’s Neulasta (pegfilgrastim).

The approval is based on data from a multicenter trial in which patients were randomized 2:1 to receive either 30 mcg of the sufentanil sublingual tablet as needed, or placebo, with treatment limited up to 48 hours following the procedure.

The committee jointly voted 21-2 against recommending approval, noting that the benefit-risk profile was not adequate to support approval.

This approval marks the first and only oral film approved by the FDA to treat seizures associated with Lennox-Gastaut syndrome.

Hyperkalemia increased the risk of 30-day readmissions.

Clobazam oral film (Sympazan) is the first and only FDA-approved oral film formulation to treat seizures associated with Lennox-Gastaut syndrome.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

This list encompasses over 50 companies in the digital health space attempting to improve medication adherence, ranging from bioingestible sensors to smart pill bottles.

The guidelines also highlight the importance of discussions between health care providers and patients.

Tanezumab (Eli Lilly and Pfizer) reduced osteoarthritis pain by 50% or greater in more than half of patients in a study.

Officials with the FDA have approved Sandoz’s adalimumab-adaz (Hyrimoz), a biosimilar of Humira.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

All-oral direct-acting antivirals had a significant effect on the clinical and economic outcomes of patients with hepatitis C virus in the 4 years following the approval of these treatments.